The centrosomal protein tax1 binding protein 2 is a novel tumor suppressor in hepatocellular carcinoma regulated by cyclin‐dependent kinase 2

Wai‐Lung Lai, Wing‐Yan Hung, Leo Lap‐Yan Wong, Yuan Zhou, Veronica Yee‐Law Leong, Joyce Man‐Fong Lee, Irene Oi‐Lin Ng, Dong‐Yan Jin, Yick‐Pang Ching – 18 May 2012 – Deregulation of cellular‐signaling pathways by the inactivation of tumor‐suppressor genes is one of the major causes of hepatocellular carcinoma (HCC). In this study, we identified Tax1 binding protein 2 (TAX1BP2) as a novel tumor‐suppressor gene in HCC.

Rare inborn errors associated with chronic hepatitis B virus infection*

Qiang Zhao, Liang Peng, Weijun Huang, Qibin Li, Yuanyuan Pei, Ping Yuan, Lingyan Zheng, Yongling Zhang, Jia Deng, Cheng Zhong, Bin Hu, Hongke Ding, Wei Fang, Ru Li, Qijun Liao, Chaoshuang Lin, Weiping Deng, Huijun Yan, Jinghui Hou, Qiuliang Wu, Tingting Xu, Jinsong Liu, Longbo Hu, Tao Peng, Suqing Chen, Kar N. Lai, Man‐Fung Yuen, Yue Wang, Mala K. Maini, Caixia Li, Miaoxin Li, Jian Wang, Xiuqing Zhang, Pak‐Chung Sham, Jun Wang, Zhi‐Liang Gao, Yiming Wang – 18 May 2012 – Chronic hepatitis B (CHB) is a major global health issue.

Outcomes after living donor liver transplantation for acute liver failure in Japan: Results of a nationwide survey

Noriyo Yamashiki, Yasuhiko Sugawara, Sumihito Tamura, Nobuaki Nakayama, Makoto Oketani, Koji Umeshita, Shinji Uemoto, Satoshi Mochida, Hirohito Tsubouchi, Norihiro Kokudo – 11 May 2012 – Nationwide surveys of acute liver failure (ALF) are conducted annually in Japan, and 20% of patients with ALF undergo liver transplantation (LT). We extracted data for 212 patients who underwent LT for ALF from the nationwide survey database of the Intractable Liver Diseases Study Group of Japan.

Variant 1 of KIAA0101, overexpressed in hepatocellular carcinoma, prevents doxorubicin‐induced apoptosis by inhibiting p53 activation

Lijuan Liu, Xiaobei Chen, Shuixiang Xie, Chuanjie Zhang, Zhenpeng Qiu, Fan Zhu – 11 May 2012 – KIAA0101 overexpression was detected in numerous malignant solid tumors and involved in tumor progression; however, the correlation between KIAA0101 expression level and human hepatocellular carcinoma (HCC) was controversial.

Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers

Ellen Hulskotte, Samir Gupta, Fengjuan Xuan, Marga van Zutven, Edward O'Mara, Hwa‐Ping Feng, John Wagner, Joan Butterton – 11 May 2012 – The hepatitis C virus protease inhibitor boceprevir is a strong inhibitor of cytochrome P450 3A4 and 3A5 (CYP3A4/5). Cyclosporine and tacrolimus are calcineurin inhibitor immunosuppressants used to prevent organ rejection after liver transplantation; both are substrates of CYP3A4. This two‐part pharmacokinetic interaction study evaluated boceprevir with cyclosporine (part 1) and tacrolimus (part 2).

Subscribe to